Patent: 10,172,808

Summary for Patent: 10,172,808

Title:	Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
Abstract:	The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36.gamma. (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Inventor(s):	Frederick; Joshua (Boston, MA), Bai; Ailin (Newton, MA), Presnyak; Vladimir (Cambridge, MA), Hoge; Stephen (Brookline, MA), Benenato; Kerry (Sudbury, MA), McFadyen; Iain (Arlington, MA), Kumarasinghe; Ellalahewage Sathyajith (Harvard, MA), Hewitt; Susannah (Jamaica Plain, MA)
Assignee:	ModernaTX, Inc. (Cambridge, MA)
Application Number:	15/995,889
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,172,808
Patent Claims:	see list of patent claims

Details for Patent 10,172,808

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2036-05-18
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2036-05-18
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2036-05-18
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2036-05-18
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017		2036-05-18
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021		2036-05-18
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034	05/18/2016		2036-05-18